This company has been marked as potentially delisted and may not be actively trading. BioTelemetry (BEAT) Competitors Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsCompetitorsEarningsHeadlinesInsider TradesShort InterestTrendsBuy This Stock BEAT vs. RCEL, ANIK, NYXH, UTMD, DRTS, PDEX, LNSR, BWAY, ARAY, and TLSIShould you be buying BioTelemetry stock or one of its competitors? The main competitors of BioTelemetry include AVITA Medical (RCEL), Anika Therapeutics (ANIK), Nyxoah (NYXH), Utah Medical Products (UTMD), Alpha Tau Medical (DRTS), Pro-Dex (PDEX), LENSAR (LNSR), BrainsWay (BWAY), Accuray (ARAY), and TriSalus Life Sciences (TLSI). These companies are all part of the "surgical & medical instruments" industry. BioTelemetry vs. AVITA Medical Anika Therapeutics Nyxoah Utah Medical Products Alpha Tau Medical Pro-Dex LENSAR BrainsWay Accuray TriSalus Life Sciences BioTelemetry (NASDAQ:BEAT) and AVITA Medical (NASDAQ:RCEL) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, institutional ownership, earnings, community ranking, media sentiment, dividends, valuation, analyst recommendations and profitability. Do insiders and institutionals have more ownership in BEAT or RCEL? 7.8% of BioTelemetry shares are owned by institutional investors. Comparatively, 27.7% of AVITA Medical shares are owned by institutional investors. 20.9% of BioTelemetry shares are owned by insiders. Comparatively, 1.8% of AVITA Medical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Does the MarketBeat Community believe in BEAT or RCEL? BioTelemetry received 308 more outperform votes than AVITA Medical when rated by MarketBeat users. However, 70.34% of users gave AVITA Medical an outperform vote while only 63.37% of users gave BioTelemetry an outperform vote. CompanyUnderperformOutperformBioTelemetryOutperform Votes39163.37% Underperform Votes22636.63% AVITA MedicalOutperform Votes8370.34% Underperform Votes3529.66% Which has higher earnings and valuation, BEAT or RCEL? BioTelemetry has higher earnings, but lower revenue than AVITA Medical. AVITA Medical is trading at a lower price-to-earnings ratio than BioTelemetry, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioTelemetryN/AN/A-$14.64M-$0.68-2.42AVITA Medical$64.25M3.79-$61.85M-$2.39-3.85 Which has more volatility and risk, BEAT or RCEL? BioTelemetry has a beta of -0.71, suggesting that its share price is 171% less volatile than the S&P 500. Comparatively, AVITA Medical has a beta of 1.6, suggesting that its share price is 60% more volatile than the S&P 500. Is BEAT or RCEL more profitable? BioTelemetry has a net margin of 0.00% compared to AVITA Medical's net margin of -96.26%. BioTelemetry's return on equity of -175.50% beat AVITA Medical's return on equity.Company Net Margins Return on Equity Return on Assets BioTelemetryN/A -175.50% -154.96% AVITA Medical -96.26%-337.91%-71.50% Does the media prefer BEAT or RCEL? In the previous week, AVITA Medical had 1 more articles in the media than BioTelemetry. MarketBeat recorded 2 mentions for AVITA Medical and 1 mentions for BioTelemetry. BioTelemetry's average media sentiment score of 0.00 equaled AVITA Medical'saverage media sentiment score. Company Overall Sentiment BioTelemetry Neutral AVITA Medical Neutral Do analysts rate BEAT or RCEL? BioTelemetry presently has a consensus target price of $8.00, suggesting a potential upside of 386.32%. AVITA Medical has a consensus target price of $17.25, suggesting a potential upside of 87.30%. Given BioTelemetry's stronger consensus rating and higher possible upside, analysts plainly believe BioTelemetry is more favorable than AVITA Medical.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioTelemetry 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00AVITA Medical 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75 SummaryBioTelemetry beats AVITA Medical on 9 of the 16 factors compared between the two stocks. Get BioTelemetry News Delivered to You Automatically Sign up to receive the latest news and ratings for BEAT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BEAT vs. The Competition Export to ExcelMetricBioTelemetrySurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$55.46M$4.04B$5.30B$7.35BDividend YieldN/A39.51%5.12%4.30%P/E Ratio-2.4227.6821.8017.80Price / SalesN/A47.06379.9697.74Price / CashN/A51.0838.2634.64Price / Book2.705.816.443.98Net Income-$14.64M$67.09M$3.21B$247.73M BioTelemetry Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BEATBioTelemetry2.491 of 5 stars$1.65-21.3%$8.00+386.3%-23.8%$55.46MN/A-2.421,700Short Interest ↓Gap UpRCELAVITA Medical1.0995 of 5 stars$7.76+3.5%$17.25+122.3%-1.8%$203.45M$64.25M-3.25130ANIKAnika Therapeutics4.0188 of 5 stars$13.92-0.6%$22.00+58.0%-45.4%$197.33M$119.91M-2.09300NYXHNyxoah2.0994 of 5 stars$5.71-6.1%$14.75+158.3%-36.9%$194.48M$4.52M-3.05110Short Interest ↑Gap UpUTMDUtah Medical Products2.7774 of 5 stars$54.39-0.8%N/A-22.7%$178.51M$40.90M13.77180Upcoming EarningsNews CoverageDRTSAlpha Tau Medical2.6535 of 5 stars$2.45-2.8%$8.00+226.5%-4.5%$172.43MN/A-5.7080Short Interest ↓News CoverageGap DownHigh Trading VolumePDEXPro-Dex1.5586 of 5 stars$52.87+3.9%$52.00-1.6%+233.1%$172.41M$61.00M26.30140Short Interest ↑Positive NewsGap DownHigh Trading VolumeLNSRLENSAR0.9728 of 5 stars$13.76-0.6%$15.00+9.0%+354.6%$162.22M$53.49M-9.42110Short Interest ↓High Trading VolumeBWAYBrainsWay3.6479 of 5 stars$8.61-2.7%$13.17+52.9%+63.2%$162.10M$41.02M86.11120Short Interest ↓Positive NewsGap DownARAYAccuray2.6482 of 5 stars$1.57flatN/A-32.4%$161.45M$453.14M-31.401,040TLSITriSalus Life Sciences2.7926 of 5 stars$5.15-1.3%$11.56+124.5%-40.9%$157.04M$29.43M-2.07106 Related Companies and Tools Related Companies AVITA Medical Alternatives Anika Therapeutics Alternatives Nyxoah Alternatives Utah Medical Products Alternatives Alpha Tau Medical Alternatives Pro-Dex Alternatives LENSAR Alternatives BrainsWay Alternatives Accuray Alternatives TriSalus Life Sciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BEAT) was last updated on 4/18/2025 by MarketBeat.com Staff From Our Partners100-year-old investment secret predicts what?!A 100-year-old indicator has quietly predicted nearly every major market meltdown — including the Dot-Com Bust...Weiss Ratings | SponsoredThe first casualty of the 2025 trade warThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored‘Wheels Are Falling Off’ the U.S. Stock MarketThe last time the U.S. economy looked like this, stocks didn't move for 16 years... And many investors lost...Stansberry Research | SponsoredRead before the next tariff announcementLarry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioTelemetry, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioTelemetry With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy BEAT Stock Free BEAT Stock Alerts